Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2Reportar como inadecuado




Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

The purpose of this studywas to analyze the effects of the treatment with Exenatide joint to insulindetemir. The study was carried out with obese patients with type 2 diabetesmellitus DM2 and deficient control, despite intensive insulin therapycombined with oral antidiabetics. A longitudinal study was made with 15patients controlled by the Endocrinology and Nutrition Section of the ReinaSofía University Hospital, Murcia. These patients were treated with Exenatide jointto insulin during 3, 6 and 12 months. Statistically meaningful differences p< 0.05 were observed in the reduction of HbA1c in the 3 and 6 monthstreatment groups initial HbA1c: 9.55% ± 1.086%, weight: 119.94 kg, insulinrequirement: 0.71 IU-kg-day; after 3 months: HbA1c: 7.77% ± 1.164%, weight:98.13 kg, insulin requirement: 0.59 IU-kg-day; after 6 months: HbA1c: 7.21%,weight: 97.93 kg, insulin requirement: 0.55 IU-kg-day. It was observed thatthe association of Exenatide and insulin promotes an improvement in severalindicators such as weight, body mass index BMI, systolic pressure SP,diastolic pressure DP, triglycerides TG, cLDL, cHDL and total cholesterolTC, in patients with diabetes resistant to conventional therapy. However,these improvements were statistically no significant p < 0.05. It ispossible to talk of a reduction of cardiovascular risk factors in patients withExenatide, being thus a suitable option for this kind of individuals. It isimportant to emphasize the fact that our study showed bigger body-weightreductions results after 6 and 12 months, as compared to the researches quoted.

KEYWORDS

Type 2 Diabetes Mellitus; Exenatide; Cardiovascular Risk; Physical and Biochemical Parameters

Cite this paper

López Ruiz, A. , Núñez Sánchez, M. , García-Talavera Espín, N. , Avilés, A. , Peso Gilsanz, C. , Sánchez, R. , Gallego García, M. , Palao, J. , Ortuño, M. , Navarro, S. and Obesity Unit of the Hospital Reina Sofía, C. 2014 Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2. Pharmacology & Pharmacy, 5, 433-443. doi: 10.4236-pp.2014.54053.





Autor: Alfonso López Ruiz*, María Ángeles Núñez Sánchez, Noelia Victoria García-Talavera Espín, Amparo Meoro Avilés, Cristina d

Fuente: http://www.scirp.org/



DESCARGAR PDF




Documentos relacionados